Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250399) titled 'A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants with Severe Asthma' on Oct. 1.
Study Type: Interventional
Study Design:
randomized controlled trial, double blind, dose comparison control, parallel assignment, treatment purpose
Primary Sponsor: Shinohara Yoshifumi
Condition:
Severe Asthma
Intervention:
Those participants in VALIANT who were receiving either 100 mg every 24 weeks (Q24W) or placebo will be randomized in a 1:1 ratio to receive verekitug (UPB-101) at doses of 100 mg every 12 weeks (Q12W) or 400 mg Q24W administered subcutaneously (SC). Those participants in...